Global Gastrointestinal Disorder Therapeutics

Gastrointestinal Disorder Therapeutics Comprehensive Study by Type (Branded, Generics), Application (Ulcerative Colitis, Crohn’s Disease, GERD, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Route (Oral, Intravenous, Others) Players and Region - Global Market Outlook to 2027

Gastrointestinal Disorder Therapeutics Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Gastrointestinal Disorder Therapeutics?
Gastrointestinal Disorder Therapeutics relates to any condition or disease that occurs in the gastrointestinal tract. The gastrointestinal tract (also known as the GI tract) is a collection of hollow organs that form a long continuous passage from our mouth to our aneurism. Our GI tract is made up of the following organs: mouth, esophagus, stomach, small intestine, large intestine, and anus. Our digestive system is made up of our GI tract, liver, pancreas, and gallbladder. An extensive network of blood vessels supplies blood to these organs while also transporting nutrients to other organs in the body. Nerves and hormones work together to regulate digestive system function, and bacteria that live in our GI tract (called gut flora or microbiome) play a role in digestion, immunity, and overall health. The digestive system organs are held in place by a membranous sac called the peritoneum.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledAstraZeneca (United Kingdom), Takeda Pharmaceutical Company (Japan), Johnson & Johnson (United States), Eisai (Japan), Abbott Laboratories (United States), Salix Pharmaceuticals (United States), Allergan plc. (Ireland), GSK plc (United Kingdom), Pfizer, Inc. (United States) and AbbVie, Inc. (United States)


The study covers a detailed analysis segmented by key business segments i.e. by type (Branded and Generics) , by application (Ulcerative Colitis, Crohn’s Disease, GERD and Others) and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Gastrointestinal Disorder Therapeutics market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Gastrointestinal Disorder Therapeutics market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are AstraZeneca (United Kingdom), Takeda Pharmaceutical Company (Japan), Johnson & Johnson (United States), Eisai (Japan), Abbott Laboratories (United States), Salix Pharmaceuticals (United States), Allergan plc. (Ireland), GSK plc (United Kingdom), Pfizer, Inc. (United States) and AbbVie, Inc. (United States).

Market Overview:
On 21St July 2021, AstraZeneca acquired Alexion Pharmaceuticals, Inc. The acquisition marks AstraZeneca's entry into medicines for rare diseases and the start of a new chapter for the company. AstraZeneca now has a stronger scientific presence in immunology and will continue to pioneer the discovery and development of medicines for patients with rare diseases through Alexion's innovative complement-biology platform and robust pipeline. Rare diseases represent a significant unmet medical need and present the company with a high-growth opportunity.
It has been proposed that FGIDs are caused by dysregulation of the enteric and central nervous systems, which affects intestinal sensation and motility. Anticholinergic medications used to treat depression, anxiety, and seizures have become increasingly appealing agents for use in FGIDs because they act on the central and peripheral nervous systems to modulate mood, visceral and neuropathic pain, as well as autonomic function.
The market for Gastrointestinal Disorder Therapeutics is moderately competitive. To gain a larger market share, these market players have extensively used competitive sustainability strategies such as new product development and regional and distribution channel expansion. Furthermore, increased emphasis on refining operations and supply chain management has enabled key players to maintain a competitive advantage. Abbott Laboratories, Abbvie Inc., AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Janssen Pharmaceuticals Inc. (Johnson & Johnson), Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc. (Salix Pharmaceuticals Inc.), Boehringer Ingelheim GmbH, and Cipla Inc. are among the market participants.

Gastrointestinal Disorder Therapeutics Market Dynamics:
AttributesDetails
Growth Drivers
  • Increasing Number of Gastrointestinal Diseases among Old Age People
  • Increasing Investment by Governments of Various Countries in the Field Of Life Science and the Healthcare Sector
Major Trends
  • Introduction of Premium-Priced Therapies for Advanced Gastrointestinal Disorder Therapeutics
  • Rising Investments and Funding In the Field Of Life Science Research
Restraints
  • High Cost of Raw Material Used In Manufacturer Gastrointestinal Disorder Therapeutics
  • Increasing Presence of the Counterfeit Drug
Road Blocks / Challenges
  • Lack of Treatment Facilities in Many Geographical Regions such as the Middle East and South Africa
  • Lack of Awareness in the Emerging Economies
Gaps & Opportunities
  • High Investment Done By the Various Practitioners and Pharmaceutical Companies
  • Increasing obese Population across the globe


Key highlights of the Global Gastrointestinal Disorder Therapeutics market Study:
• CAGR of the market during the forecast period 2021-2027
• In-depth information on growth factors that will accelerate the Gastrointestinal Disorder Therapeutics market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Gastrointestinal Disorder Therapeutics market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Gastrointestinal Disorder Therapeutics Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Gastrointestinal Disorder Therapeutics market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Gastrointestinal Disorder Therapeutics market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Gastrointestinal Disorder Therapeutics Supplier & Distributor, Government Bodies, Research Institutes and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Type
  • Branded
  • Generics
By Application
  • Ulcerative Colitis
  • Crohn’s Disease
  • GERD
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Route
  • Oral
  • Intravenous
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Gastrointestinal Diseases among Old Age People
      • 3.2.2. Increasing Investment by Governments of Various Countries in the Field Of Life Science and the Healthcare Sector
    • 3.3. Market Challenges
      • 3.3.1. Lack of Treatment Facilities in Many Geographical Regions such as the Middle East and South Africa
      • 3.3.2. Lack of Awareness in the Emerging Economies
    • 3.4. Market Trends
      • 3.4.1. Introduction of Premium-Priced Therapies for Advanced Gastrointestinal Disorder Therapeutics
      • 3.4.2. Rising Investments and Funding In the Field Of Life Science Research
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gastrointestinal Disorder Therapeutics, by Type, Application, Distribution Channel, Route and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Gastrointestinal Disorder Therapeutics (Value)
      • 5.2.1. Global Gastrointestinal Disorder Therapeutics by: Type (Value)
        • 5.2.1.1. Branded
        • 5.2.1.2. Generics
      • 5.2.2. Global Gastrointestinal Disorder Therapeutics by: Application (Value)
        • 5.2.2.1. Ulcerative Colitis
        • 5.2.2.2. Crohn’s Disease
        • 5.2.2.3. GERD
        • 5.2.2.4. Others
      • 5.2.3. Global Gastrointestinal Disorder Therapeutics by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Gastrointestinal Disorder Therapeutics by: Route (Value)
        • 5.2.4.1. Oral
        • 5.2.4.2. Intravenous
        • 5.2.4.3. Others
      • 5.2.5. Global Gastrointestinal Disorder Therapeutics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Gastrointestinal Disorder Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Takeda Pharmaceutical Company (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eisai (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbott Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Salix Pharmaceuticals (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Allergan plc. (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GSK plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AbbVie, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Gastrointestinal Disorder Therapeutics Sale, by Type, Application, Distribution Channel, Route and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Gastrointestinal Disorder Therapeutics (Value)
      • 7.2.1. Global Gastrointestinal Disorder Therapeutics by: Type (Value)
        • 7.2.1.1. Branded
        • 7.2.1.2. Generics
      • 7.2.2. Global Gastrointestinal Disorder Therapeutics by: Application (Value)
        • 7.2.2.1. Ulcerative Colitis
        • 7.2.2.2. Crohn’s Disease
        • 7.2.2.3. GERD
        • 7.2.2.4. Others
      • 7.2.3. Global Gastrointestinal Disorder Therapeutics by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Gastrointestinal Disorder Therapeutics by: Route (Value)
        • 7.2.4.1. Oral
        • 7.2.4.2. Intravenous
        • 7.2.4.3. Others
      • 7.2.5. Global Gastrointestinal Disorder Therapeutics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gastrointestinal Disorder Therapeutics: by Type(USD Million)
  • Table 2. Gastrointestinal Disorder Therapeutics Branded , by Region USD Million (2016-2021)
  • Table 3. Gastrointestinal Disorder Therapeutics Generics , by Region USD Million (2016-2021)
  • Table 4. Gastrointestinal Disorder Therapeutics: by Application(USD Million)
  • Table 5. Gastrointestinal Disorder Therapeutics Ulcerative Colitis , by Region USD Million (2016-2021)
  • Table 6. Gastrointestinal Disorder Therapeutics Crohn’s Disease , by Region USD Million (2016-2021)
  • Table 7. Gastrointestinal Disorder Therapeutics GERD , by Region USD Million (2016-2021)
  • Table 8. Gastrointestinal Disorder Therapeutics Others , by Region USD Million (2016-2021)
  • Table 9. Gastrointestinal Disorder Therapeutics: by Distribution Channel(USD Million)
  • Table 10. Gastrointestinal Disorder Therapeutics Hospital Pharmacies , by Region USD Million (2016-2021)
  • Table 11. Gastrointestinal Disorder Therapeutics Retail Pharmacies , by Region USD Million (2016-2021)
  • Table 12. Gastrointestinal Disorder Therapeutics Online Pharmacies , by Region USD Million (2016-2021)
  • Table 13. Gastrointestinal Disorder Therapeutics: by Route(USD Million)
  • Table 14. Gastrointestinal Disorder Therapeutics Oral , by Region USD Million (2016-2021)
  • Table 15. Gastrointestinal Disorder Therapeutics Intravenous , by Region USD Million (2016-2021)
  • Table 16. Gastrointestinal Disorder Therapeutics Others , by Region USD Million (2016-2021)
  • Table 17. South America Gastrointestinal Disorder Therapeutics, by Country USD Million (2016-2021)
  • Table 18. South America Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 19. South America Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 20. South America Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 21. South America Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 22. Brazil Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 23. Brazil Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 24. Brazil Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 25. Brazil Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 26. Argentina Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 27. Argentina Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 28. Argentina Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 29. Argentina Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 30. Rest of South America Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 31. Rest of South America Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 32. Rest of South America Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 33. Rest of South America Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 34. Asia Pacific Gastrointestinal Disorder Therapeutics, by Country USD Million (2016-2021)
  • Table 35. Asia Pacific Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 36. Asia Pacific Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 37. Asia Pacific Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 38. Asia Pacific Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 39. China Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 40. China Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 41. China Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 42. China Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 43. Japan Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 44. Japan Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 45. Japan Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 46. Japan Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 47. India Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 48. India Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 49. India Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 50. India Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 51. South Korea Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 52. South Korea Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 53. South Korea Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 54. South Korea Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 55. Australia Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 56. Australia Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 57. Australia Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 58. Australia Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 59. Rest of Asia-Pacific Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 60. Rest of Asia-Pacific Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 61. Rest of Asia-Pacific Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 62. Rest of Asia-Pacific Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 63. Europe Gastrointestinal Disorder Therapeutics, by Country USD Million (2016-2021)
  • Table 64. Europe Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 65. Europe Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 66. Europe Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 67. Europe Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 68. Germany Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 69. Germany Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 70. Germany Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 71. Germany Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 72. France Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 73. France Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 74. France Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 75. France Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 76. Italy Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 77. Italy Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 78. Italy Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 79. Italy Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 80. United Kingdom Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 81. United Kingdom Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 82. United Kingdom Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 83. United Kingdom Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 84. Netherlands Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 85. Netherlands Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 86. Netherlands Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 87. Netherlands Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 88. Rest of Europe Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 89. Rest of Europe Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 90. Rest of Europe Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 91. Rest of Europe Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 92. MEA Gastrointestinal Disorder Therapeutics, by Country USD Million (2016-2021)
  • Table 93. MEA Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 94. MEA Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 95. MEA Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 96. MEA Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 97. Middle East Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 98. Middle East Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 99. Middle East Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 100. Middle East Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 101. Africa Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 102. Africa Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 103. Africa Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 104. Africa Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 105. North America Gastrointestinal Disorder Therapeutics, by Country USD Million (2016-2021)
  • Table 106. North America Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 107. North America Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 108. North America Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 109. North America Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 110. United States Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 111. United States Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 112. United States Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 113. United States Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 114. Canada Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 115. Canada Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 116. Canada Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 117. Canada Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 118. Mexico Gastrointestinal Disorder Therapeutics, by Type USD Million (2016-2021)
  • Table 119. Mexico Gastrointestinal Disorder Therapeutics, by Application USD Million (2016-2021)
  • Table 120. Mexico Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2016-2021)
  • Table 121. Mexico Gastrointestinal Disorder Therapeutics, by Route USD Million (2016-2021)
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Gastrointestinal Disorder Therapeutics: by Type(USD Million)
  • Table 133. Gastrointestinal Disorder Therapeutics Branded , by Region USD Million (2022-2027)
  • Table 134. Gastrointestinal Disorder Therapeutics Generics , by Region USD Million (2022-2027)
  • Table 135. Gastrointestinal Disorder Therapeutics: by Application(USD Million)
  • Table 136. Gastrointestinal Disorder Therapeutics Ulcerative Colitis , by Region USD Million (2022-2027)
  • Table 137. Gastrointestinal Disorder Therapeutics Crohn’s Disease , by Region USD Million (2022-2027)
  • Table 138. Gastrointestinal Disorder Therapeutics GERD , by Region USD Million (2022-2027)
  • Table 139. Gastrointestinal Disorder Therapeutics Others , by Region USD Million (2022-2027)
  • Table 140. Gastrointestinal Disorder Therapeutics: by Distribution Channel(USD Million)
  • Table 141. Gastrointestinal Disorder Therapeutics Hospital Pharmacies , by Region USD Million (2022-2027)
  • Table 142. Gastrointestinal Disorder Therapeutics Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 143. Gastrointestinal Disorder Therapeutics Online Pharmacies , by Region USD Million (2022-2027)
  • Table 144. Gastrointestinal Disorder Therapeutics: by Route(USD Million)
  • Table 145. Gastrointestinal Disorder Therapeutics Oral , by Region USD Million (2022-2027)
  • Table 146. Gastrointestinal Disorder Therapeutics Intravenous , by Region USD Million (2022-2027)
  • Table 147. Gastrointestinal Disorder Therapeutics Others , by Region USD Million (2022-2027)
  • Table 148. South America Gastrointestinal Disorder Therapeutics, by Country USD Million (2022-2027)
  • Table 149. South America Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 150. South America Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 151. South America Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 152. South America Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 153. Brazil Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 154. Brazil Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 155. Brazil Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 156. Brazil Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 157. Argentina Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 158. Argentina Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 159. Argentina Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 160. Argentina Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 161. Rest of South America Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 162. Rest of South America Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 163. Rest of South America Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 164. Rest of South America Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 165. Asia Pacific Gastrointestinal Disorder Therapeutics, by Country USD Million (2022-2027)
  • Table 166. Asia Pacific Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 167. Asia Pacific Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 168. Asia Pacific Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 169. Asia Pacific Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 170. China Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 171. China Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 172. China Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 173. China Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 174. Japan Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 175. Japan Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 176. Japan Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 177. Japan Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 178. India Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 179. India Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 180. India Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 181. India Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 182. South Korea Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 183. South Korea Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 184. South Korea Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 185. South Korea Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 186. Australia Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 187. Australia Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 188. Australia Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 189. Australia Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 190. Rest of Asia-Pacific Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 191. Rest of Asia-Pacific Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 192. Rest of Asia-Pacific Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 193. Rest of Asia-Pacific Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 194. Europe Gastrointestinal Disorder Therapeutics, by Country USD Million (2022-2027)
  • Table 195. Europe Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 196. Europe Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 197. Europe Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 198. Europe Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 199. Germany Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 200. Germany Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 201. Germany Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 202. Germany Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 203. France Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 204. France Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 205. France Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 206. France Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 207. Italy Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 208. Italy Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 209. Italy Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 210. Italy Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 211. United Kingdom Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 212. United Kingdom Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 213. United Kingdom Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 214. United Kingdom Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 215. Netherlands Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 216. Netherlands Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 217. Netherlands Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 218. Netherlands Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 219. Rest of Europe Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 220. Rest of Europe Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 221. Rest of Europe Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 222. Rest of Europe Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 223. MEA Gastrointestinal Disorder Therapeutics, by Country USD Million (2022-2027)
  • Table 224. MEA Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 225. MEA Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 226. MEA Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 227. MEA Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 228. Middle East Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 229. Middle East Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 230. Middle East Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 231. Middle East Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 232. Africa Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 233. Africa Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 234. Africa Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 235. Africa Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 236. North America Gastrointestinal Disorder Therapeutics, by Country USD Million (2022-2027)
  • Table 237. North America Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 238. North America Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 239. North America Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 240. North America Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 241. United States Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 242. United States Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 243. United States Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 244. United States Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 245. Canada Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 246. Canada Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 247. Canada Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 248. Canada Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 249. Mexico Gastrointestinal Disorder Therapeutics, by Type USD Million (2022-2027)
  • Table 250. Mexico Gastrointestinal Disorder Therapeutics, by Application USD Million (2022-2027)
  • Table 251. Mexico Gastrointestinal Disorder Therapeutics, by Distribution Channel USD Million (2022-2027)
  • Table 252. Mexico Gastrointestinal Disorder Therapeutics, by Route USD Million (2022-2027)
  • Table 253. Research Programs/Design for This Report
  • Table 254. Key Data Information from Secondary Sources
  • Table 255. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gastrointestinal Disorder Therapeutics: by Type USD Million (2016-2021)
  • Figure 5. Global Gastrointestinal Disorder Therapeutics: by Application USD Million (2016-2021)
  • Figure 6. Global Gastrointestinal Disorder Therapeutics: by Distribution Channel USD Million (2016-2021)
  • Figure 7. Global Gastrointestinal Disorder Therapeutics: by Route USD Million (2016-2021)
  • Figure 8. South America Gastrointestinal Disorder Therapeutics Share (%), by Country
  • Figure 9. Asia Pacific Gastrointestinal Disorder Therapeutics Share (%), by Country
  • Figure 10. Europe Gastrointestinal Disorder Therapeutics Share (%), by Country
  • Figure 11. MEA Gastrointestinal Disorder Therapeutics Share (%), by Country
  • Figure 12. North America Gastrointestinal Disorder Therapeutics Share (%), by Country
  • Figure 13. Global Gastrointestinal Disorder Therapeutics share by Players 2021 (%)
  • Figure 14. Global Gastrointestinal Disorder Therapeutics share by Players (Top 3) 2021(%)
  • Figure 15. Global Gastrointestinal Disorder Therapeutics share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. AstraZeneca (United Kingdom) Revenue: by Geography 2021
  • Figure 19. Takeda Pharmaceutical Company (Japan) Revenue, Net Income and Gross profit
  • Figure 20. Takeda Pharmaceutical Company (Japan) Revenue: by Geography 2021
  • Figure 21. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 22. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 23. Eisai (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Eisai (Japan) Revenue: by Geography 2021
  • Figure 25. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott Laboratories (United States) Revenue: by Geography 2021
  • Figure 27. Salix Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 28. Salix Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 29. Allergan plc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 30. Allergan plc. (Ireland) Revenue: by Geography 2021
  • Figure 31. GSK plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GSK plc (United Kingdom) Revenue: by Geography 2021
  • Figure 33. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer, Inc. (United States) Revenue: by Geography 2021
  • Figure 35. AbbVie, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. AbbVie, Inc. (United States) Revenue: by Geography 2021
  • Figure 37. Global Gastrointestinal Disorder Therapeutics: by Type USD Million (2022-2027)
  • Figure 38. Global Gastrointestinal Disorder Therapeutics: by Application USD Million (2022-2027)
  • Figure 39. Global Gastrointestinal Disorder Therapeutics: by Distribution Channel USD Million (2022-2027)
  • Figure 40. Global Gastrointestinal Disorder Therapeutics: by Route USD Million (2022-2027)
  • Figure 41. South America Gastrointestinal Disorder Therapeutics Share (%), by Country
  • Figure 42. Asia Pacific Gastrointestinal Disorder Therapeutics Share (%), by Country
  • Figure 43. Europe Gastrointestinal Disorder Therapeutics Share (%), by Country
  • Figure 44. MEA Gastrointestinal Disorder Therapeutics Share (%), by Country
  • Figure 45. North America Gastrointestinal Disorder Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca (United Kingdom)
  • Takeda Pharmaceutical Company (Japan)
  • Johnson & Johnson (United States)
  • Eisai (Japan)
  • Abbott Laboratories (United States)
  • Salix Pharmaceuticals (United States)
  • Allergan plc. (Ireland)
  • GSK plc (United Kingdom)
  • Pfizer, Inc. (United States)
  • AbbVie, Inc. (United States)
Additional players considered in the study are as follows:
Bayer AG (Germany) , Cipla Inc (India) , Valeant Pharmaceuticals (Canada) , Janssen Pharmaceuticals (Belgium) , Others
Select User Access Type

Key Highlights of Report


Aug 2022 202 Pages 57 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gastrointestinal Disorder Therapeutics Quantitative research analysis
Global Gastrointestinal Disorder Therapeutics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Gastrointestinal Disorder Therapeutics Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Gastrointestinal Disorder Therapeutics market is dominated by United States Players and may generate healthy valuation by 2027.
  • Increasing Number of Gastrointestinal Diseases among Old Age People
  • Increasing Investment by Governments of Various Countries in the Field Of Life Science and the Healthcare Sector
dominated the Gastrointestinal Disorder Therapeutics market. This is attributable to growing trend of "Introduction of Premium-Priced Therapies for Advanced Gastrointestinal Disorder Therapeutics "

Know More About Global Gastrointestinal Disorder Therapeutics Report?

Have a Query? Click Here

Other Related Reports

Biologics Outsourcing Comprehensive Study by Type (Antibody, Recombinant, Protein, Vaccines, Others), Application (Vaccine & Therapeutics Development, Blood & Blood Related Products Testing, Cellular...
$ 3650
Dental Preventive Supplies Comprehensive Study by Type (Toothpaste, Mouthwash, Dental Sealants, Dental Prophylaxis, Others), Distribution Channel (Online {E-Commerce}, Offline {Hospital Pharmacies, P...
$ 3650
Cancer Genome Sequencing Comprehensive Study by Type (Second Generation (SOLiD Sequencing, Pyro-Sequencing, Bridge Amplification Sequencing Technology), Third Generation (Ion Semiconductor Sequencing...
$ 3650
Rehabilitation Swimming Pools Comprehensive Study by Type (Portable, Stationary), Treatment Type (Orthopedics, Obesity Crisis, Sports Rehabilitation, Others), End User (Human, Veterinary) Players and...
$ 3500
Patient Engagement Technology Comprehensive Study by Application (Health Management, Social and Behavioral, Home Health), Technology (Licensing fees, Implementation fees, Annual license maintenance f...
$ 3750
Lung Cancer Vaccines - Comprehensive Study by Type (Preventive Lung Cancer Vaccines, Therapeutic Lung Cancer Vaccines), Application (Hospitals, Clinics, Pharmacies, Vaccines Centers, Other, End user)...
$ 3450